Subtle or not warning of more patience required. If reading for...

Subtle or not warning of more patience required. If reading for the first time, it would read pretty exciting IMO. Long termer's either sick of waiting or in my case resigned to more waiting - the half yearly will be interesting to see if they have manged to expand Scenesse - they have a Manager directly involved in that process. A little concerning I didn't catch anything on extension of label for adolescents? Neutracthal?
They have some key investor engagements in the next few months so hope they generate some interest, The Soiree's have done zero by the looks.
Perhaps they could reach out to Taylor Swift as an influencer? It will be interesting who they come up with as the marketing program develops.
No significant alternative revenue stream for another 12 months? Excited to see the results using Prenumbra in stroke and looks to be a useful product for different dosing going forward. No real bad news just time.
As an aside, 2 companies often referred here -NEU =in trading halt dropped off quite a bit due to company shorting Arcadia regarding NEU's product. PME reached heights of almost $110 -now around $86 after half year. Not a segment for the faint of heart but that's investing for you. GLTA